Lupus & antiphospholipid syndrome
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
Authors' conclusion
Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling, including apoptotic, innate and adaptive mechanisms that play key roles in SLE immunopathogenesis.
Study context
- Population
- Patients with moderate to severe systemic lupus erythematosus (SLE) enrolled in TULIP-1 and TULIP-2RNA sequencing (RNA-seq): anifrolumab n=244, placebo n=258
- Comparison
- Intravenous anifrolumab vs placebo alongside standard therapy
- Outcome
- Transcriptomic and proteomic modulation, anifrolumab vs placebo
Methodological detailsgene expression and proteomic analysis of two phase 3 trials (TULIP-1 and TULIP-2), randomised, 52-week, longitudinal
- Gene expression and proteomic analysis of two phase 3 trials (TULIP-1 and TULIP-2)
- Randomised
- 52-week
- Longitudinal
Main finding
As reported in the abstract
Genes modulated by week 24 (overlapping results at week 52)
>2000
Proteins modulated by week 52
41
Original publication
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Ann Rheum Dis. Published 15 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →